Efgartigimodmyasthenia gravisMG
… and assessed their capacity to mediate pathomechanisms.Results Efgartigimod decreased all detectable AChR-specific IgG subclasses. At basel…
5articles mentioning drugs
31drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: efgartigimod ×
efgartigimod
This drug is selected. Its supporting articles are shown below.
Articles mentioning efgartigimod
5 articles · page 1 of 1efgartigimodPLEXneonatal Fc receptor antagonistsMyasthenia gravisInstitutional Review Board of Punan HospitalNSISTgMG
…thogenic mediators, while neonatal Fc receptor antagonists (eg, efgartigimod) offer novel therapeutic potential. Both PLEX and efgartigimod …
efgartigimodrecombinant human hyaluronidase PH20rHuPH20PH20 SCHealth Assessment QuestionnaireSystemic SclerosisSystemic sclerosis (SSc)NCT06655155interstitial lung disease
…SSc will be randomized 2:1 to receive weekly administrations of efgartigimod or placebo PH20 SC (coformulated with recombinant human hyaluro…
efartigimodefgartigimodIV efartigmodefgartigmodSC efartigmodIV efargartigmodefgartigmodMethodsNHNNResultsNHNNgeneralised MG (gMG)+1 more
…100 patients treated to date. Subcutaneous (SC) preparations of efartigimod have been available in the UK since March 2024Aim To describe t…
OCSEFGefgartigimodmyasthenia gravis
…y dataset.Results 169 adults (≥18 years) who were using chronic OCS pre-EFG initiation, initiated EFG by December 31, 2022, and con…